Semaglutide vs Tirzepatide: GLP-1 Agonist Comparison
Semaglutide and tirzepatide are the two leading incretin-based compounds, but they differ at a fundamental level. Semaglutide targets only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors simultaneously. This difference in receptor pharmacology translates to measurable differences in clinical trial outcomes. The head-to-head SURPASS-2 trial provided direct comparison data, though it tested semaglutide at its diabetes strength rather than its weight-management strength, which complicates the interpretation.
This comparison is structured to highlight practical differences in research context, mechanisms, and use-case fit.
By Maylene · Page updated
Semaglutide
A GLP-1 receptor agonist developed by Novo Nordisk. FDA-approved for diabetes (2017) and weight management (2021). Backed by the STEP and SUSTAIN trial programs involving thousands of participants.
Tirzepatide
The first dual GLP-1/GIP receptor agonist, developed by Eli Lilly. FDA-approved for diabetes (2022) and weight management (2023). SURMOUNT trials showed the largest pharmacological weight reduction ever recorded.
Side-by-Side Comparison
Use this table as a quick screening tool before reading the detailed sections below.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 only (single agonist) | GLP-1 + GIP (dual agonist) |
| Developer | Novo Nordisk | Eli Lilly |
| Average Weight Loss | ~15% (STEP 1, 68 weeks) | ~22.5% (SURMOUNT-1, 72 weeks) |
| HbA1c Reduction | Up to 1.8% (SUSTAIN trials) | Up to 2.58% (SURPASS trials) |
| CV Outcomes Data | SELECT trial: 20% MACE reduction | Pending dedicated CV outcomes trial |
| GI Side Effects | ~44% nausea rate | ~30-50% nausea rate |
| Half-life | ~7 days | ~5 days |
The Dual vs Single Agonist Question
The core scientific question here is whether activating GIP receptors alongside GLP-1 receptors provides meaningful clinical advantages. The SURMOUNT data suggests it does, with weight loss numbers roughly 50% higher than what semaglutide achieved in its trials. However, comparing across trials has limitations. The SURPASS-2 head-to-head trial directly compared tirzepatide with the diabetes strength of semaglutide, not its weight-management strength, and tirzepatide was superior in all three tirzepatide arms.
Cardiovascular Evidence
Semaglutide currently has a significant advantage in cardiovascular outcomes data. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in participants without diabetes. Tirzepatide does not yet have a completed dedicated cardiovascular outcomes trial, though the SURPASS-4 study showed cardiovascular safety. For researchers focused on cardiometabolic endpoints, semaglutide has the more established evidence base.
Tolerability and Side Effects
Both compounds cause gastrointestinal side effects, primarily nausea, that generally improve over time. Some researchers have hypothesized that tirzepatide's GIP component may partially counteract GLP-1-mediated nausea, but clinical trial rates for nausea are broadly similar between the two compounds.
The Verdict
Tirzepatide produces larger weight reductions in clinical trials, likely due to its dual-receptor mechanism. Semaglutide has a more established cardiovascular evidence base and longer track record. Neither is definitively superior across all endpoints. The choice depends on which outcomes matter most for a given research question.
Frequently Asked Questions
Which produces more weight loss?
Tirzepatide. In their respective Phase 3 trials, tirzepatide produced approximately 22.5% average weight loss (SURMOUNT-1) compared to semaglutide's 15% (STEP 1). However, these were separate trials with slightly different designs.
Have they been compared head-to-head?
Yes. SURPASS-2 compared tirzepatide with the diabetes strength of semaglutide, not its higher weight-management strength. Tirzepatide was superior in both HbA1c reduction and weight loss in all three tirzepatide arms.
Which has better cardiovascular data?
Semaglutide. The SELECT trial showed a 20% reduction in major cardiovascular events. Tirzepatide has demonstrated cardiovascular safety but does not yet have a completed dedicated CV outcomes trial.
Can they be used together in research?
They target overlapping receptor systems, so combining them is not a standard research approach. They would likely compete for GLP-1 receptor binding, making the pharmacology difficult to interpret.
Sources & evidence
These papers describe the stated compounds and study models. They do not test or certify Maylene products. Animal or cell findings do not establish human benefit, and pharmaceutical trials do not validate research-only pens.
- STEP 1 semaglutide trial — Wilding et al., 2021
Randomized human trial of a specific pharmaceutical formulation with clinical supervision and lifestyle intervention.
- SURMOUNT-1 tirzepatide trial — Jastreboff et al., 2022
Randomized human trial in adults with obesity or overweight and a related condition; results are specific to the study treatment.
Research Disclaimer
This comparison is for educational and informational purposes only. All information is based on published scientific research. Peptides sold by Maylene are intended solely for laboratory research use and are not for human consumption. Consult healthcare professionals before making any health decisions.
Research These Peptides
Open the current listing for each compound the catalogue stocks, then compare product details and availability.
Semaglutide is not in the current catalogue.
View All PeptidesMore Comparisons
Keep exploring related matchups to validate your shortlist across multiple dimensions.
Start Your Research Today
Compare current listings, labelled content and product documentation before ordering.
All compounds are supplied for laboratory and scientific research use only.
Shop Peptides